Oak Hill Biosciences

formerly Oak Hill Bio

Advancing Rare Disease Therapies Across the Finish Line

Cambridge, United States · Founded 2024 · $32.5M raised

Headquarters
Cambridge
Founded
2024
Business Model
B2B
Total Funding
$32.5M
Last Round
$32.5M Series AJun 2026
Rounds
1

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Oak Hill Bio is a clinical-stage biotechnology company that acquires and develops outstanding rare-disease drug candidates deprioritized by large pharmaceutical companies. Its lead asset, rugonersen (OHB-724), is a Phase 3-ready antisense oligonucleotide licensed from Roche for Angelman syndrome, a rare neurodevelopmental disease with significant unmet need.

Summary

Oak Hill Biosciences is a Biotech company based in Cambridge, United States, founded in 2024. It has raised $32.5M in total across 1 round, most recently a $32.5M Series A round in Jun 2026. Investors include Balyasny Asset Management, Janus Henderson Investors and venBIO Partners.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AJun 2026
$32.5M

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Oak Hill Biosciences on Indexed.vc
<a href="https://indexed.vc/companies/oak-hill-biosciences"><img src="https://indexed.vc/api/badge/company/oak-hill-biosciences" alt="Oak Hill Biosciences on Indexed.vc" width="260" height="76" /></a>